Company intelligence / Profile preview

ProBiotix Health

Pontefract, England, United Kingdom

Ownership: Private
Development stage: Other

Overview

ProBiotix Health has completed at least three independent human clinical studies demonstrating that its lead probiotic strain Lactobacillus plantarum ECGC13110402 (LPLDL) can reduce total cholesterol, LDL cholesterol and apolipoprotein B by around 30% and improve multiple cardiometabolic biomarkers; these data support commercial CholBiome finished products now marketed globally.[1][6]

Therapeutic areas: OtherCardiovascularWomen's HealthMetabolic Disorders
Modalities: Live biotherapeutic product therapyMicrobial therapyBiologic
Industry: Biotech

Partnerships

OptiBiotix Health (historical parent and online distribution partner)[6]Granja Pocha (Yo-Life probiotic yoghurt brand in Uruguay)[6]Nutraconnect Pte Ltd (Asia-Pacific commercialisation partner)[6]SymbioPharm (probiotic brand partner in Germany)[6]

Beyond the preview

Go deeper on ProBiotix Health.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on ProBiotix Health.

Explore the full profile